{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-025452","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.630702+00:00","generated_at":"2026-06-13T04:37:19.130952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Champions Oncology reports Q4 revenue $13.1M (+2% YoY); full-year record $53.9M but operating loss widens","bullets":["Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.","Full-year operating loss $5.3M vs income $607M; adjusted EBITDA loss $1.3M vs +$3.1M.","Gross margin fell to 44% (Q4) and 45% (FY) from 52% in prior-year periods due to study cancellations.","Cash $10.1M, no debt; CFO projects return to profitability in H2 of current fiscal year.","Announced formation of wholly owned biotech subsidiary Corellia AI for therapeutic drug discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-025452","json":"https://secwatch.observer/filing/0001628280-23-025452.json","markdown":"https://secwatch.observer/filing/0001628280-23-025452.md","text":"https://secwatch.observer/filing/0001628280-23-025452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/csbr-20230724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:37:19.130952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c3de8bc0feb3587597d1f95c420ba863eecfe1f","claim":"CHAMPIONS ONCOLOGY, INC. reported fiscal year ended April 30, 2023 results: revenue $53.9 million.","evidence_excerpt":"Total revenue for fiscal year 2023 was $53.9 million, an increase of 10%, compared to $49.1 million for fiscal year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended April 30, 2023"},{"label":"Revenue","value":"$53.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f91fd6ffa6fc98df2c4ecfc33dd6bf2e72dc4d98","claim":"CHAMPIONS ONCOLOGY, INC. reported three months ended April 30, 2023 results: revenue $13.1 million.","evidence_excerpt":"Total revenue for the fourth quarter of fiscal 2023 was $13.1 million, an increase of 2%, compared to $12.9 million for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended April 30, 2023"},{"label":"Revenue","value":"$13.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}